Heart Failure Treatment Market

Brandessence Market Research has published a new report title and According to Study “The global heart failure treatment market in terms of revenue was worth of USD 80.2 Billion in 2020 and is expected to reach USD 109.1 Billion in 2027, growing at a CAGR of 3.90% from 2021 to 2027. The global heart failure treatment market is expected to grow at a significant growth rate due to several driving factors.

Heart failure can be caused by coronary artery disease, heart attack, cardiomyopathy, and high blood pressure. In the heart, failure heart has not stopped working.  In this condition, the heart works less efficiently than normal working. Because of several reasons, blood moves through the heart and body slower rate, and pressure in the heart increases. As a result, the heart cannot pump enough oxygen and nutrients to meet the body's needs. The corners of the heart can be stretched or stiffened and tightened to allow more blood to flow into the body. Some of treatments include: heart valve repair or replacement, coronary bypass surgery, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT), or biventricular pacing, heart transplant, ventricular assist devices (VADs) and others.

The study provides a crucial view of the global heart failure treatment market by segmenting the market based on type, treatment, end-user, and region & country level. Based upon type heart failure treatment market is segmented into acute heart failure and chronic heart failure. Based upon treatment, heart failure treatment market is segmented into drugs and devices. Based upon the end-user, heart failure treatment market is segmented into hospitals, ambulatory surgical centers, clinics, and others. The regions covered in the global heart failure treatment market are North America, Europe, Asia-Pacific, and the Rest of the World. Based on the country level, the global heart failure treatment market is sub-divided into U.S., Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Brazil, Mexico, GCC, Africa, etc.

Rising prevalence of cardiovascular disorders, the launch of several heart failure drugs, and the growing aging population are some of the major factors driving the market growth. For example; according to the world health organization cardiovascular diseases are one of the most life-taking diseases. One person dies every 36 seconds in the United States from cardiovascular disease. Additionally, increasing number of product offerings for heart failure treatment is also supplementing the market growth. For example; recently in 2020; FDA approved a new drug that is Farxiga oral tablet. It is useful for adults with heart failure with reduced ejection fraction to reduce the risk of cardiovascular death and hospitalization for heart failure. Moreover, the growing aging population is also another factor augmenting the heart failure treatment market growth. However, side effects associated with the consumption of heart failure medication is one of may hamper the market growth within the forecast period.

Segmentation Analysis of Heart Failure Treatment Market

The type segment of the global heart failure treatment market is dominated by Chronic Heart Failure with the largest market share of 61.73% in 2020. The treatment segment of the global heart failure treatment market is dominated by drugs with the largest market share of XX% in 2020. The end-user segment of global heart failure treatment is dominated by in-patinet with the largest share of 58.78% in the year 2020.

Global Heart Failure Treatment Market: By Type

• Acute Heart Failure
• Chronic Heart Failure

Global Heart Failure Treatment Market: By Treatment

• Drugs
• Devices
• Others

Global Heart Failure Treatment Market: By End User

• In Patient
• Out Patient Care
• Out Patient Investigation
• Drugs
• Primary Care

North America is expected to dominate the heart failure treatment market within the forecast period due to the increasing number of heart failure cases, an increasing number of cardiovascular diseases, and the rapidly growing geriatric population. Over the few years, the number of cases of cardiovascular diseases is increasing. For example; About 5.7 million adults in the United States have heart failure. Moreover, every year, 805,000 Americans have a heart attack, 605,000 of them for the first time. Europe and the Asia Pacific regions are expected to emerge as the fastest-growing regional market owing to the increasing geriatric population in these regions and the increasing risk of heart failure. For example; more than one-fifth (21.2 %) of people aged 65-74 years in Europe were obese in 2017.

Global Heart Failure Treatment Market: Market Player Analysis

• Medtronic Plc
• Boston Scientific Corporation
• AstraZeneca
• Novatis
• Boehringer Ingelheim
• Eli Lilly and Company
• Amgen
• Others

Click Here to know more about Companies

Market Trends of Heart Failure Treatment

As heart failure is a life threatening disease and addressing it should be considered as a global health priority. According to “The Global Heart Failure Awareness Program” by Novartis Pharma AG, approximately 26 million people are living with heart failure worldwide. So as heart failure is a chronic disease, it needs lifelong management. However, with treatment, signs and symptoms of heart failure can improve and the heart sometimes becomes stronger as treatment may help patients to live longer and reduce the chance of dying suddenly. Doctors usually treat heart failure with a combination of medications, which is depending on patient’s symptoms. Some of the medications used are such as Angiotensin-converting enzyme (ACE) inhibitors, Beta blockers, Angiotensin II receptor blockers, Aldosterone antagonists, Diuretics, Inotropes, Digoxin (Lanoxin). Also, in some cases, doctors recommend surgery as a treatment to cure the underlying problem that directed to heart failure. Some treatments being studied and used in certain people that include heart valve repair or replacement, coronary bypass surgery, implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT), or biventricular pacing, heart transplant, ventricular assist devices (VADs) and others. In addition, doctors may recommend palliative care in treatment plan.

Some of the major trends of Global Heart Failure Treatment Market are:

a) Left Ventricular Assist Device (LVAD): Many patients are being considered for advanced therapies including left ventricular assist devices (LVADs) with the present morbidity and mortality associated with chronic heart failure. Although initially it was used as a bridge to transplant & this LVAD indications have expanded beyond bridge to transplant to bridge to recovery, destination therapy (DT) and bridge to (transplant) candidacy. The mortality of patients with end‐stage heart failure has been improved by LVADs. For instance; According to Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) from 2006 to 2016, an estimated about 17,634 LVADs has been implanted. Thus, with given increasing number of LVAD implantations nationwide, emergency physicians are increasingly likely to encounter them in practice. This analyses the continuous flow LVADs presently implanted and their forthcoming significance to emergency physicians.

b) Cardiac Implantable Electronic Devices (CIEDs): As remote monitoring (RM) has significantly transformed the standard of care for patients with cardiac electronic implantable devices, cardiovascular implantable electronic devices (CIEDs) are essential management options for patients with heart failure with associated optimal pharmacotherapy. These CIEDs have evolved beyond treatment of bradycardias to include resynchronisation therapies for heart failure, monitoring devices for various arrhythmias and defibrillators to prevent sudden arrhythmic death. Cardiovascular implantable electronic devices (CIEDs) have become the keystone of management for patients with brady- or tachyarrhythmias and heart failure (HF) with reduced ejection fraction (EF) and this is associated with the emergence of complex stimulation systems such as pacemakers (PMs), cardiac resynchronization therapy (CRT), implantable cardioverter–defibrillators (ICDs) and the growing number of patients with different indications treated with CIEDs.

c) Intra-atrial Shunt Devices: To unload the right atrium and reduce pulmonary venous pressure which is hypothesized to be beneficial in patients with heart failure with preserved ejection fraction (HFpEF) this inter-atrial shunt device (IASD) is designed. It is one of the most exciting new device concepts; the use of a transcatheter delivered intra-atrial shunt device (IASD) to lower left atrial pressure by creating a small left atrial to right atrial shunt. To reduce left atrial pressure in HFpEF, insertion of an interatrial shunt device (IASD) has been shown to be associated with short‐term haemodynamic and symptomatic benefit. It is a safe device compared with a sham control treatment in patients with heart failure and ejection fraction equal to or greater than 40%.

d) Artificial Intelligence for HF Patients: As new technologies have been recently introduced to improve the monitoring of patients with chronic syndromes such as heart failure and that may improve heart failure management & reduce costs, the new devices are employed to collect large amounts of data & data processing through artificial intelligence techniques. The analysis of large datasets using an artificial intelligence technique is leading to a standard shift in the era of precision medicine. This trend has recently emerged to cover the diagnostic & therapeutic methods for including more complex ways of data collection & processing, thus, to hold the potential to achieve a greater understanding of HF pathophysiology and to enhance patient care. It includes telemedicine or telehealth that applied to HF diseases that is rapidly growing and aims to improve & individualise patient care as well as reducing financial costs. This telehealth is a broad term that encompasses the different applications of telematics to medicine by allowing diagnosis or remote treatment through a set of communication tools.

e) Wearable Technologies: As nearly everyone now carries a smartphone and millions of people use wearable devices to track their health by using devices such as Apple Watch or Fitbit devices as most wearables are marketed to consumers & can measure movement, heart rate and blood pressure to detect and monitor arrhythmia and support exercise training and rehabilitation. These wearable technologies with different devices directed at healthcare professionals that include ECG patch recorders & vests, patches and textiles with in-built sensors for improved prognostication and the early detection of acute decompensations. These advanced wearable technological devices provide potentially new solutions to HF care, for example-titrating diuretics and other drug therapy based on pulmonary artery pressure data from an implantable monitor that can be interrogated remotely with CardioMEMS device significantly reduces HF hospitalization in patients with at least moderately severe symptoms. This trend is emerging with improved precision, accuracy and reliability of such devices and the data may be used in decision-making by healthcare professionals.

  Report Coverage

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2021 - 2027
Market Size in 2020:	USD 80.2 Billion
Base year considered	2020
Forecast Period CAGR %:	3.90 %
Market Size Expected in 2027:	USD 109.1 Billion
Tables, Charts & Figures:	175
Pages	200
Key Players/Companies	Medtronic Plc,Boston Scientific Corporation,AstraZeneca,Novatis,Boehringer Ingelheim,Eli Lilly and Company,Amgen,Others
Segments Covered	By Product Type, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Heart Failure Treatment Market By Regional & Country Level:

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy

Asia Pacific

• China
• Japan
• India
• Southeast Asia

Latin America

• Brazil
• Mexico

Middle East and Africa

• GCC
• Africa
• Rest of Middle East and Africa